Dr. Veerendra Koppolu is a senior scientist in the Department of Biologics Development at AstraZeneca in Gaithersburg, Maryland, USA. Dr. Koppolu finished his doctoral degree from University of Kansas, USA. Dr. Koppolu is a honorary faculty member at non-profit organization Novel Global Community Education Foundation (NGCEF) focused in guiding doctoral students.
Dr. Koppolu’s primary research interests include pre-clinical and clinical development of small molecules, monoclonal antibodies, bispecifics, and antibody drug conjugates as therapeutic treatment for various cancers and infectious diseases. At AstraZeneca, Dr. Koppolu helped in development of drug Durvalumab, an FDA approved drug that prevents tumor immune suppression and benefit patients suffering from urinary bladder cancer. Dr. Koppolu also worked in development of immunotherapeutic vaccine candidates for triple negative breast cancer, and small molecule compounds as novel antimicrobials for Enterotoxigenic Escherichia coli and Shigella flexneri. Dr. Koppolu has worked towards obtaining many NIH academic and small business grants. Dr. Koppolu has published over 46 papers including research article, review articles, abstracts, book chapters, and books. Dr. Koppolu is serving as reviewer/editor of 25 peer-reviewed international journals covering oncology and infectious disease areas. Dr. Koppolu is a member of American Association of Cancer Research (AACR), American Chemical Society (ACS), American Association of Microbiology (ASM)